Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length - PubMed (original) (raw)
Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length
O Hansson et al. J Neurochem. 2001 Aug.
Free article
Abstract
Transgenic Huntington's disease (HD) mice, expressing exon 1 of the HD gene with an expanded CAG repeat, are totally resistant to striatal lesion induced by excessive NMDA receptor activation. We now show that striatal lesions induced by the mitochondrial toxin malonate are reduced by 70-80% in transgenic HD mice compared with wild-type littermate controls. This occurred in 6- and 12-week-old HD mice with 150 CAG repeats (line R6/2) and in 18-week-old, but not 6-week-old, HD mice with 115 CAG repeats (line R6/1). Therefore, we show for the first time that the resistance to neurotoxin in transgenic HD mice is dependent on both the CAG repeat length and the age of the mice. Importantly, most HD patients develop symptoms in adulthood and exhibit an inverse relationship between CAG repeat length and age of onset. Transgenic mice expressing a normal CAG repeat (18 CAG) were not resistant to malonate. Although endogenous glutamate release has been implicated in malonate-induced cell death, glutamate release from striatal synaptosomes was not decreased in HD mice. Malonate-induced striatal cell death was reduced by 50-60% in wild-type mice when they were treated with either the NMDA receptor antagonist MK-801 or the caspase inhibitor zVAD-fmk. These two compounds did not reduce lesion size in transgenic R6/1 mice. This might suggest that NMDA receptor- and caspase-mediated cell death pathways are inhibited and that the limited malonate-induced cell death still occurring in HD mice is independent of these pathways. There were no changes in striatal levels of the two anti cell death proteins Bcl-X(L) and X-linked inhibitor of apoptosis protein (XIAP), before or after the lesion in transgenic HD mice. We propose that mutant huntingtin causes a sublethal grade of metabolic stress which is CAG repeat length-dependent and results in up-regulation over time of cellular defense mechanisms against impaired energy metabolism and excitotoxicity.
Similar articles
- Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J, Landwehrmeyer GB, Lüesse HG, Sprünken A, Puls C, Milkereit A, Milkereit E, Kosinski CM. Schiefer J, et al. Mov Disord. 2002 Jul;17(4):748-57. doi: 10.1002/mds.10229. Mov Disord. 2002. PMID: 12210870 - Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z, Wang HB, Deng YP, Lei WL, Xie JP, Meade CA, Del Mar N, Goldowitz D, Reiner A. Sun Z, et al. Neurobiol Dis. 2005 Dec;20(3):907-17. doi: 10.1016/j.nbd.2005.05.023. Epub 2005 Jun 28. Neurobiol Dis. 2005. PMID: 15990326 - Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I. Zhang H, et al. Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16. Neurobiol Dis. 2008. PMID: 18502655 Free PMC article. - Transgenic models of Huntington's disease.
Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP. Sathasivam K, et al. Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):963-9. doi: 10.1098/rstb.1999.0447. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434294 Free PMC article. Review. - Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
Lee CY, Cantle JP, Yang XW. Lee CY, et al. FEBS J. 2013 Sep;280(18):4382-94. doi: 10.1111/febs.12418. Epub 2013 Jul 31. FEBS J. 2013. PMID: 23829302 Free PMC article. Review.
Cited by
- The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.
Li JY, Popovic N, Brundin P. Li JY, et al. NeuroRx. 2005 Jul;2(3):447-64. doi: 10.1602/neurorx.2.3.447. NeuroRx. 2005. PMID: 16389308 Free PMC article. Review. - Single nuclei RNA-seq reveals a medium spiny neuron glutamate excitotoxicity signature prior to the onset of neuronal death in an ovine Huntington's disease model.
Jiang A, You L, Handley RR, Hawkins V, Reid SJ, Jacobsen JC, Patassini S, Rudiger SR, Mclaughlan CJ, Kelly JM, Verma PJ, Bawden CS, Gusella JF, MacDonald ME, Waldvogel HJ, Faull RLM, Lehnert K, Snell RG. Jiang A, et al. Hum Mol Genet. 2024 Aug 18;33(17):1524-1539. doi: 10.1093/hmg/ddae087. Hum Mol Genet. 2024. PMID: 38776957 Free PMC article. - Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.
Gu X, André VM, Cepeda C, Li SH, Li XJ, Levine MS, Yang XW. Gu X, et al. Mol Neurodegener. 2007 Apr 30;2:8. doi: 10.1186/1750-1326-2-8. Mol Neurodegener. 2007. PMID: 17470275 Free PMC article. - Killer proteases and little strokes--how the things that do not kill you make you stronger.
O'Duffy AE, Bordelon YM, McLaughlin B. O'Duffy AE, et al. J Cereb Blood Flow Metab. 2007 Apr;27(4):655-68. doi: 10.1038/sj.jcbfm.9600380. Epub 2006 Aug 9. J Cereb Blood Flow Metab. 2007. PMID: 16896349 Free PMC article. Review. - Mitochondrial calcium function and dysfunction in the central nervous system.
Nicholls DG. Nicholls DG. Biochim Biophys Acta. 2009 Nov;1787(11):1416-24. doi: 10.1016/j.bbabio.2009.03.010. Epub 2009 Mar 17. Biochim Biophys Acta. 2009. PMID: 19298790 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials